SOURCE: Hansen Medical, Inc.

Hansen Medical, Inc.

April 16, 2010 09:00 ET

Hansen Medical Announces Pricing of Public Offering of Common Stock

MOUNTAIN VIEW, CA--(Marketwire - April 16, 2010) - Hansen Medical, Inc. (NASDAQ: HNSN) today announced that it has priced its public offering of 14,000,000 shares of its common stock at a price to the public of $2.00 per share. Hansen Medical has granted the underwriter a 30-day over-allotment option to purchase on the same terms and conditions up to an additional 2,100,000 shares of common stock. The gross proceeds to Hansen Medical, before expenses, from the sale of shares, are expected to be $28,000,000 assuming the 30-day over-allotment option is not exercised. The closing of the offering is expected to take place on April 21, 2010. Piper Jaffray & Co. will be the sole underwriter for the offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on January 22, 2010 that became effective on February 12, 2010 and a preliminary prospectus supplement relating to the offering that was filed with the Securities and Exchange Commission on April 15, 2010.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The offering of securities may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the prospectus supplement and accompanying prospectus may be obtained upon request to Piper Jaffray & Co., at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, Calif., develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the Sensei™ Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The Sensei system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data and was cleared by the U.S. Food and Drug Administration in May 2007 for manipulation and control of certain mapping catheters in electrophysiology procedures. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, statements relating to expectations, projections, estimates, goals, plans, objectives and future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements. Factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in greater detail under the heading "Risk Factors" contained in our preliminary prospectus supplement filed with the Securities and Exchange Commission on April 15, 2010 and in our periodic SEC filings, including our Annual Report on Form 10-K filed with the SEC on March 16, 2010. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact Information